From the Guidelines
Kisqali (ribociclib) and simvastatin should not be used together due to a significant drug interaction, as Kisqali can increase simvastatin levels in the bloodstream, potentially leading to serious side effects. If you are taking Kisqali for breast cancer treatment, you should avoid simvastatin and consider alternative statins like pravastatin or rosuvastatin. This interaction occurs because Kisqali, like other tyrosine kinase inhibitors, can inhibit CYP3A4, an enzyme that metabolizes simvastatin, as seen with imatinib which increases simvastatin's maximum plasma concentration (Cmax) and area under the curve (AUC) due to CYP3A4 inhibition 1.
The use of simvastatin with drugs that inhibit CYP3A4, such as Kisqali, can lead to increased levels of simvastatin in the body, which may cause muscle damage (rhabdomyolysis), kidney problems, and liver injury. This is similar to the interaction between amiodarone and simvastatin, where concomitant use resulted in a significant increase in simvastatin and simvastatin acid AUC and Cmax, leading to an increased risk of myopathy and rhabdomyolysis 2.
Given the potential for serious adverse effects, it is crucial to avoid the combination of Kisqali and simvastatin. If the use of both medications is necessary, your healthcare provider should carefully evaluate the risks and benefits, possibly adjusting the simvastatin dose or monitoring you more closely for side effects. Always inform your healthcare provider about all medications you're taking, including over-the-counter drugs and supplements, to avoid dangerous interactions.
Key considerations for managing this interaction include:
- Avoiding the use of simvastatin with Kisqali whenever possible
- Considering alternative statins that are not metabolized by CYP3A4, such as pravastatin or rosuvastatin
- Carefully monitoring patients for signs of muscle toxicity or other adverse effects if the combination cannot be avoided
- Adjusting the dose of simvastatin or the frequency of monitoring based on the individual patient's risk factors and the specific circumstances of their treatment.
From the Research
Kisqali and Simvastatin Interaction
- Kisqali, also known as ribociclib, is a medication used in the treatment of certain types of cancer, including breast cancer.
- Simvastatin is a statin medication used to lower cholesterol and triglyceride levels in the blood.
- According to a study published in the Journal of oncology pharmacy practice 3, there is a possible drug-drug interaction between ribociclib and simvastatin that can increase the risk of severe rhabdomyolysis.
- The study suggests that ribociclib can inhibit the metabolism of simvastatin, leading to increased levels of simvastatin in the blood and potentially causing toxicity.
- Another study published in FP essentials 4 notes that drug-drug interactions, including those involving statins, can cause significant adverse effects and increase the risk of hospitalizations.
- A study published in The Medical clinics of North America 5 highlights the importance of understanding drug interactions in preventive cardiology, including those involving statins, to prevent hospitalizations, mortality, and health care costs.
Mechanism of Interaction
- Ribociclib is a strong inhibitor of CYP 3A4 and a potential inhibitor of OATP1B1 membrane transporter, which can affect the metabolism and transport of simvastatin 3.
- The interaction between ribociclib and simvastatin can lead to increased levels of simvastatin in the blood, potentially causing toxicity and increasing the risk of severe rhabdomyolysis.
Clinical Implications
- The concomitant use of simvastatin with ribociclib should be avoided or careful monitoring of creatine kinase is warranted to prevent severe rhabdomyolysis 3.
- Healthcare professionals should be aware of the potential drug-drug interactions involving statins and other medications, including ribociclib, to optimize patient care and prevent adverse effects 6, 4, 5.